Archive ouverte HAL - HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome

HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome

Cristina Belizna 1, 2 Francesca Pregnolato 3 Sébastien Abad 4, 5 Jaume Alijotas-Reig 6 Howard Amital 7 Zahir Amoura 8 Laura Andreoli 9 Emmanuel Andres 10 Achile Aouba 11 Sule Apras Bilgen 12 Laurent Arnaud 10 Boris Bienvenu 13 Viktoria Bitsadze 14 Patrick Blanco 15 Miri Blank 7 Maria Borghi 16 Antonia Caligaro 17 Elisabeta Candrea 18 Valentina Canti 16 Laurent Chiche 19 Jean Chrétien 1 Jan Willem Cohen Tervaert 20, 21 Laura Damian 22 Teresa Delross 17 Emmanuelle Dernis 23 Katrien Devreese 24 Aleksandra Djokovic 25 Enrique Esteve-Valverde 26 Maria Favaro 17 Céline Fassot 27, 28 Raquel Ferrer-Oliveras 6 Alban Godon 1 Mohamed Hamidou 29 Milena Hasan 30 Daniel Henrion 27, 28 Bernard Imbert 31 Pierre Yves Jeandel 32 Pascale Jeannin 1 Patrick Jego 33 Noemie Jourde-Chiche 34 Jamilya Khizroeva 35 Olivier Lambotte 36, 37 Cédric Landron 38 Jose Omar Latino 39 Estibaliz Lazaro 40 Karina De Leeuw 41 Thomas Le Gallou 33 Levent Kiliç 12 Maarten Limper 42 Laurent Loufrani 27, 28 Romain Lubin 27, 28 Nadine Magy-Bertrand 43 Guillaume Mahé 44, 33 Alexander Makatsariya 35 Thierry Martin 10 Christian Muchardt 45 Gyorgy Nagy Loukman Omarjee 44, 33 Pieter Van Paasen 46 Gilles Pernod 47 Florence Perrinet Gilberto Pïres Rosa 48 Marc Antoine Pistorius 29 Amelia Ruffatti 17 Fatma Said 49 Patrick Saulnier 1 Damien Sene 50 Loïc Sentilhes 51 Ova Shovman 7 Jean Sibilia 52 Crina Sinescu 53 Natasa Stanisavljevic 25 Ljudmila Stojanovich 25 Lai Shan Tam 54 Angela Tincani 9 Fréderic Tollis 55 Sebastian Udry 39 Marie Noelle Ungeheuer 56 Mathilde Versini 57 Ricard Cervera 58 Pier Luigi Meroni 16
Abstract : The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%–21% at 5 years in thrombotic APS and 20–28% in obstetrical APS [2, 3]. Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and anti-thrombotic various effects [4–16]. Our group recently obtained the orphan designation of HCQ in antiphospholipid syndrome by the European Medicine Agency. Furthermore, the leaders of the project made the proposal of an international project, HIBISCUS, about the use of Hydroxychloroquine in secondary prevention of obstetrical and thrombotic events in primary APS. This study has been launched in several countries and at now, 53 centers from 16 countries participate to this international trial. This trial consists in two parts: a retrospective and a prospective study. The French part of the trial in thrombosis has been granted by the French Minister of Health in December 2015 (the academic trial independent of the pharmaceutical industry PHRC N PAPIRUS) and is coordinated by one of the members of the leading consortium of HIBISCUS.
Type de document :
Article dans une revue
Autoimmunity Reviews, Elsevier, 2018, 17 (12), pp.1153 - 1168. 〈10.1016/j.autrev.2018.05.012〉
Liste complète des métadonnées

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01936357
Contributeur : Laurent Jonchère <>
Soumis le : mardi 27 novembre 2018 - 13:33:16
Dernière modification le : vendredi 15 mars 2019 - 10:40:03

Identifiants

Citation

Cristina Belizna, Francesca Pregnolato, Sébastien Abad, Jaume Alijotas-Reig, Howard Amital, et al.. HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmunity Reviews, Elsevier, 2018, 17 (12), pp.1153 - 1168. 〈10.1016/j.autrev.2018.05.012〉. 〈hal-01936357〉

Partager

Métriques

Consultations de la notice

142